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Interest in using bacteriophages to control the growth and spread of bacterial pathogens
is being revived in the wake of widespread antibiotic resistance. However, little is known
about the ecological effects that high concentrations of phages in the environment might
have on natural microbial communities.We review the current evidence suggesting phage-
mediated environmental perturbation, with a focus on agricultural examples, and describe
the potential implications for human health and agriculture. Speciﬁcally, we examine the
known and potential consequences of phage application in certain agricultural practices,
discuss the risks of evolved bacterial resistance to phages, and questionwhether the future
of phage therapywill emulate that of antibiotic treatment in termsofwidespread resistance.
Finally, we propose some basic precautions that could preclude such phenomena and
highlight existing methods for tracking bacterial resistance to phage therapeutic agents.
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INTRODUCTION
The selection for and subsequent evolution of antibiotic resistance
in bacterial populations, both in the wider environment and dur-
ing clinical treatment, presents a serious challenge to humanhealth
(Kåhrström, 2013). Although still controversial, it is increasingly
clear that agricultural use of antibiotics has played a role in the
continued selection for resistance genes and that the movement
of these genes into pathogens of clinical relevance is possible
(see Smith et al., 2009; van Cleef et al., 2010; Heuer et al., 2011;
Zhu et al., 2013). Nosocomial environments also act as signiﬁcant
sources of antibiotic resistance and the transfer of antibiotic resis-
tance genes into the agricultural environment has recently been
demonstrated, suggesting the genetic exchange between environ-
ments works both ways (Price et al., 2012). As a result, alternative
antimicrobial strategies are being sought. One such strategy is
to utilize naturally occurring viral predators of bacteria: bacte-
riophages (phages). Lytic phages are capable of killing bacteria
by invading and propagating within the host cell and then lysing
open the cell to “burst” out, thus killing the bacteria. This is in
contrast to temperate phages, which integrate into the genome of
their hosts and can be transmitted vertically, serving as a refuge
for phages in harsh environments (Svircev et al., 2011). The latter,
although important to the ecology and evolution of bacterial pop-
ulations, are not commonly considered for use as biocontrol and
therefore will not be covered further in this review (but see Hyman
and Abedon, 2010 for review of the effects of lysogeny on bacte-
rial resistance). Despite being discovered as potential therapeutic
agents over 80 years ago (d’Herelle, 1929), and their continual use
in Russia and Georgia ever since (Kutter et al., 2010), few clinical
trials of so-called “phage therapy” have been conducted in West-
ern medicine (Wright et al., 2009; Sarker et al., 2012). Accordingly,
no clinical phage therapy products are currently available in the
West, and regulatory burdensmay have dampened pharmaceutical
interest, as years of research and clinical trials can cost millions of
euros, presenting a formidable hurdle (Pirnay et al., 2011; Brüssow,
2012).
A more viable route to market has been provided by use
of phages in agriculture and aquaculture (Jones et al., 2012;
Martínez-Díaz and Hipólito-Morales, 2013). Recent review sug-
gests that although phage therapy will not be the panacea that
broad-spectrum antibiotics once were, phages could nonetheless
play an important role in treating infections and maintaining
food yields (Allen et al., 2013). Indeed, phage usage in agricul-
ture has shown promise for treating numerous plant pathogens
(Frampton et al., 2012), and some formulations of phages
have been sold for large-scale environmental application (e.g.,
AgriPhageTM, Omnilytics). Likewise, the Food and Drug Admin-
istration in the USA has approved a product for the treatment
of food products prior to market (ListshieldTM, Intralytix) and
classed the use of phages in this speciﬁc context as “gener-
ally recognized as safe” (Food and Drug Administration (FDA),
2013). Another fruitful avenue for phage therapy may be
aquaculture, an industry that has increased globally by over
10-fold in the last 30 years (Food and Agriculture Organi-
zation [FAO], 2012). Microbial diseases represent a severe
threat to aquaculture productivity; accordingly, phages capa-
ble of lysing pathogens such as Flavobacterium psychrophilum,
the causative agent of bacterial cold-water disease, have been
isolated and tested as therapeutic agents (Kim et al., 2010).
Combined, the scope for phage therapy to ﬁll food produc-
tion and clinical niches left vacant by redundant antibiotics
seems vast. However, whilst phage therapy as a biopesti-
cide could prove a useful tool, it also presents a risk for
repeating the mistakes made with overuse of antibiotics, and
the subsequently high levels of evolved antimicrobial resis-
tance observed both in the environment and in hospitals
(Zhu et al., 2013). For example, it is unclear whether introducing
high concentrations of diverse phage types into the environment
will select for broad resistance,making future treatments less likely
to succeed. Furthermore, the role of phage-mediated selection in
shaping bacterial growth rates and virulence to their hosts remains
poorly understood.
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Despite a number of reviews highlighting the need for increased
understanding of environmental perturbations from anthro-
pogenic antibiotic input (Martínez, 2008; Ding and He, 2010;
Allen et al., 2013), the impact of antibiotic use on microbial
communities has rarely been taken into account when design-
ing treatment or application. This is particularly surprising given
the known natural importance of these chemicals in shaping
competition among bacterial strains (D’Costa et al., 2011). As
phages are also known to select for resistant bacteria (Buckling
and Rainey, 2002) and to mediate competition among strains
(Bohannan and Lenski, 2000; Koskella et al., 2012), the same risks
should apply to this alternative treatment. Unfortunately, little
is currently known about the effects of applying high titers of
phages to natural microbial communities. Most importantly, it
is possible that with uncontrolled application of phages in the
environment the future efﬁcacy of phage therapy in a clinical set-
ting could be reduced – a mistake we cannot afford given the
need for new antimicrobial therapies as a result of drug-resistant
pathogens (Levy and Marshall, 2004). Phage therapy in agri-
culture could serve as a testing ground for clinical use (Stone,
2002; Levin and Bull, 2004). However, there could also be a
conﬂict of interest if cross-resistance to phage treatments is pos-
sible and if these resistant bacteria can spread from agricultural
to clinical settings, as has been observed for antibiotic resistance
(van Cleef et al., 2010; Perry and Wright, 2013). If phage therapy
treatments fail, or improper use of phages in the environment goes
unchecked, the use of widespread phage biocontrol in agriculture
could jeopardize the future of phage therapy in hospitals. Fortu-
nately, our understanding of phage-mediated selection is growing
at a rapid pace and a new era of genomic investigation should allow
monitoring of microbial communities following phage therapy. In
this review, we will discuss the status of the ﬁeld of phage therapy
and consider the implications of phage host range and bacterial
resistance. We suggest that with a few precautions phage therapy
may be effective for treating bacterial infections in agriculture,
aquaculture, healthcare, food production and food safety.
THE RISKS OF ANTIMICROBIAL USE IN AGRICULTURE
The argument against using antibiotics as standard agricultural
practice, both to improve growth rates and prevent disease,
is not new (Witte, 1998) and has been extensively reviewed
previously (Singer et al., 2003). However, unequivocally demon-
strating increased resistance as a consequence of agricultural
usage has proved elusive (Perry and Wright, 2013). A wave of
new data supporting both direct and indirect routes of antibi-
otic resistance genes between agricultural and human populations
suggests a bidirectional zoonotic exchange (Price et al., 2012).
For example, recent studies have found diverse and abundant
resistance genes in manure prior to disposal in the environment
(Zhu et al., 2013) and a high prevalence of resistance to mul-
tiple antibiotics in enterobacteria isolated from tomato farms
(Micallef et al., 2013) and in bacteria from manure-amended
soils (Popowska et al., 2012). Furthermore, methicillin-resistant
Staphylococcus aureus (MRSA) rates in workers on swine farms
have been shown to be higher than for the average popu-
lation in both North America and Europe (Voss et al., 2005;
Khanna et al., 2008; Smith et al., 2009; van Cleef et al., 2010).
Finally, calves treated with antibiotics are also more likely to carry
MRSA and there is a direct association between intensity of ani-
mal contact and human MRSA carriage (Graveland et al., 2010).
A similar trend is seen in aquaculture where bacteria nearer to
farms were found to have higher levels of antibiotic resistance than
nearby coastal regions in Italy (Labella et al., 2013). The increasing
number of studies supporting the hypothesis that environmental
use of antibiotics has contributed to selection for antibiotic resis-
tance suggests that non-prudent use of antibiotics in healthcare
and agriculturemay reduce the effectiveness of antibiotic strategies
as an essential treatment for disease.
As an alternative to antibiotic use, the application of phages
in agriculture is being trialed as a biopesticide to control plant
pathogens of tomato (Jones et al., 2012), citrus (Balogh et al.,
2008), and onion (Lang et al., 2007) among others (reviewed
in Svircev et al., 2011). For example, Erwinia amylovora (the
causative agent of ﬁre blight) infections are affecting a number
of crop species in orchards across North America and Europe
(see Malnoy et al., 2012 for review). Although antibiotics have
traditionally been employed to control this disease, the emer-
gence of streptomycin resistant strains (McManus et al., 2002)
and a desire to reduce antibiotic use in the environment has led
to the use of phages as an alternative. Phage biocontrol clearly
has the potential to control ﬁre blight infections, as lytic phages
have been isolated that are highly infective to the pathogen,
but deﬁnitive ﬁeld trials are currently lacking. Given the evi-
denced risks of movement of antibiotic resistance genes between
agricultural to human pathogens, we should ask whether the
large-scale application of phages is likely to repeat these past
mistakes. Until appropriate studies are conducted, the subse-
quent consequences of applying phages in agriculture for the
spread of antibiotic resistance, the evolution of the pathogen, and
the community of microbes within the plants and soil remain
unknown.
DESIGN AND IMPLEMENTATION OF PHAGE THERAPY AND
BIOCONTROL
The process of preparing a phage therapy product for clinical use
has been thoroughly described (Merabishvili et al., 2009; Gill and
Hyman, 2010). Figure 1 also describes this process for clinical
and environmental samples. Brieﬂy, environmental samples such
as sewage or clinical samples from infected wounds are collected.
The next step normally employs an“enrichment”process whereby
the target bacterial species is added to the sample to increase the
titer of phages infective to this strain. The sample is either ﬁl-
tered or chloroform is added to separate phages from bacteria, and
individual phage “plaques” (i.e., the localized absence of bacterial
growth in a lawn due to lysis) are chosen for further character-
ization. Transmission electron microscopy may be employed to
assign family level phylogeny and genetic sequencing for ﬁner
scale taxonomic assignment, and screening of virulence factors
is typically conducted. Other properties such as stability across
a range of environmental conditions may be tested for optimal
storage and production. Importantly, phage host range is typically
tested to ensure the selected isolates have high efﬁcacy against the
pathogen of interest. However, this screening is most often done
using a reference panel of laboratory stocks, rather than a large
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FIGURE 1 |Typical production of phage biopesticide.
subset of bacteria from the local environment in which the phages
will be applied, leading to a biased host range description. There-
fore one way to reduce the possible community-level effects of
applying phages would be to perform large-scale host range anal-
yses across a biologically meaningful panel of isolates (i.e., those
bacterial strains and species with which the phages are likely to
interact once applied), as has been done successfully in the ﬁeld
of microbial ecology (Flores et al., 2011; Koskella and Meaden,
2013).
Once individual phages have been isolated and characterized,
phage cocktails are produced by combining multiple, usually
phylogenetically diverse, phages into one formulation. The idea
behind these combined treatments is twofold: ﬁrst, the use of
multiple phages should increase the breadth of efﬁcacy of the
treatment to include most circulating strains of a pathogen; and
second, the evolution of bacterial resistance should be slowed
relative to single phage treatment. Whilst this approach could
select for broadly resistant bacterial hosts, a number of studies
suggest that broad resistance will carry a larger cost and there-
fore will not spread as rapidly (Bohannan and Lenski, 2000;
Hall et al., 2012; Koskella et al., 2012). For example, strains of
the plant pathogen, Pseudomonas syringae, evolved in the pres-
ence of three phage types were just as likely to evolve resistance
against all three as those strains evolved in the presence of a
single phage type. Furthermore, bacteria treated with multiple
phages were no more likely to be cross-resistant to novel phages
but were found to have paid a greater cost for their resistance
than bacteria treated with a single phage type (Koskella et al.,
2012). A similar result was observed for Pseudomonas aeruginosa
strains treated with one versus four phages (Hall et al., 2012).
This emulates the common practice of using combined antibi-
otic treatment to decrease the likelihood of evolved antibiotic
resistance (Traugott et al., 2011; Vardakas et al., 2013). Overall, a
greater understanding of the costs of resistance to phage predation
and of synergistic effects among phages in controlling bacterial
pathogens will allow for a more informed development and appli-
cation of treatment, and ideally the prevention of widespread
resistance.
THE IMPLICATIONS OF EVOLVED RESISTANCE TO PHAGES
Despite the promise of many phage therapy trials, the use of
phages to control bacterial pathogen begs the question: could the
evolution of phage resistance mirror the evolution and spread of
antibiotic resistance? Numerous studies have shown that natural
phages are well-adapted to their local bacterial populations (Vos
et al., 2009; Koskella et al., 2011) and that bacteria in turn adapt
to resist their local phages (Kunin et al., 2008; Koskella, 2013).
However, a recent review of phage resistance as a result of pro-
longed phage therapy (Ormälä and Jalasvuori, 2013) concludes
that, as it is possible to isolate phages infective to bacteria from
different geographical locations and evolutionary histories (e.g.,
Flores et al., 2011), long-term resistance need not be a concern as a
diverse set of phages capable of infectingnewly resistant strainswill
always be available. Local phage diversity is often high (Breitbart
and Rohwer, 2005), so infective phages should be easy to isolate
from just a few environmental samples. However, this parallels
the problems of antibiotic discovery – the process from discovery
to a useable product is arduous and expensive, so despite a ready
source of infective phages few companies are investing in treat-
ments (Brüssow, 2012). If bacterial resistance to phage infection
emerges rapidly and production is slow, redundancy of treatments
seems likely. As pointed out by Pirnay et al. (2011) a reactive phage
therapy program that is capable of rapidly isolating, screening, and
applying infective phages will be better placed to respond to phage
resistance than the slow and expensive process of approval and
licensing for each phage type.
Currently themaximumbreadthof bacterial resistance tophage
(i.e., the number of phage types a single bacterium is capable of
resisting) remains largely unknown, as novel genera of phages are
continually being discovered (Holmfeldt et al., 2013). For exam-
ple, the ubiquitous marine bacterial clade SAR116 was thought
to be so abundant as a result of escaping phage predation, but
a recent ﬁnding shows that it is indeed infected by phages, and
that these phages are likely to be the most abundant species on
the planet (Kang et al., 2013). Our knowledge of phage ecology
and evolution is still in its infancy; the exact mechanisms of infec-
tion, and in turn resistance, are often unknown and could be
simultaneously diverse among strains and yet largely conserved
across genera (Koskella and Meaden, 2013). There are a number
of published cases of phages that are capable of infecting bac-
terial hosts across genera (Table 1), suggesting the potential for
shared resistance mechanisms. Even if unlikely, evolved resistance
to the few phage therapy products available to clinicians would
severely impair treatment potential. This problem may be exacer-
bated by the more stringent control of phage products for clinical
use, and thus the slow pipeline from isolation to delivery, relative
to the approval of cocktails for use in agriculture. As such, rapidly
responding regulation, like the measures in place for seasonal ﬂu
vaccines (Verbeken et al., 2012), could be a more effective way of
countering phage therapy product redundancy.
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Table 1 | Examples of phages isolated from the environment capable of infecting across genera.
Author/s (year) Genera infected Number of genera Pathogenicity
Koskella and Meaden (2013) Pseudomonas and Erwinia 2 Crop pathogens
Lu et al. (2012) Lactobacillus andWeissella 2 Endocarditis and bacteremia
Evans et al. (2010) Serratia and Pantoea 2 NA
Bielke et al. (2007) Salmonella and Klebsiella or Escherichia 2 Enterocolitis, pneumonia, urinary tract infections,
and septicemia
Beumer and Robinson (2005) Sphaerotilus and Pseudomonas 2 Pneumonia, urinary tract infections, septicemia,
and wound infection
Thomas et al. (2002) Gordonia, Nocardia, and Rhodococcus 3 Opportunistic pathogenesis
Jensen et al. (1998) Pseudomonas and Sphaerotilus or
Escherichia
2 Pneumonia, urinary tract infections, septicemia,
wound infection, and enteric disease
Tilley et al. (1990) Multiple genera within the
Micromonospora
3 Respiratory infection
Finally, the combined use of phages and antibiotics has
shown great promise due to the negative pleiotropic effects of
phage resistance and antibiotic resistance. Experimental evolution
has demonstrated that phages applied to populations of Pseu-
domonas ﬂuorescens that had evolved antibiotic resistance reduced
population densities to a greater degree than when applied to sen-
sitive strains (Escobar-Páramo et al., 2012). In addition, combined
treatment was shown to drastically hinder the evolution of bacte-
rial resistance over time compared to antibiotic treatment alone
(Zhang andBuckling,2012). Inpoultry, the combinationof phages
and enroﬂoxacin resulted in lower mortality in infected birds than
either treatment individually (Huff et al., 2004). Therefore, one
potential step forward in controlling the spread of both antibi-
otic resistance and phage resistance in the environment and/or
under clinical settings could be the carefully planned combination
treatments of the two.
PHAGE-MEDIATED ATTENUATION OF BACTERIAL VIRULENCE
A common refrain of phage therapy and biocontrol is that even if
resistance does emerge, such resistance is likely to be costly, and
as such would attenuate bacterial virulence in a eukaryotic host
(Inal, 2003; Hagens et al., 2004). Phage resistance does seem to
be correlated with a reduction in metabolic ﬁtness both in the
lab (Bohannan and Lenski, 2000; Koskella et al., 2012) and the
soil (Gómez and Buckling, 2011), however the effect this may
have on virulence in a eukaryotic host is largely unknown. Of
the few examples, phage-resistant strains of Yersinia pestis have
been shown to have attenuated virulence in a mouse model sys-
tem, resulting in a signiﬁcant increase in time to death, and
in some cases complete attenuation (Filippov et al., 2011). The
same phenomenon has been observed in aquaculture with a
direct correlation observed between phage resistance and com-
plete attenuation of F. columnare in a zebraﬁsh system, such
that one phage-sensitive phenotype resulted in 100% mortality
compared to 0% in the phage-resistant phenotypes (Laanto et al.,
2012).
In plant pathogens, there is also evidence to suggest that phage-
mediated selection might alter the infectivity and/or virulence
of bacterial pathogens. Phages infecting the bacterium, Erwinia
amylovora, were found to be most efﬁcient at infecting strains
that produced either high or low levels of exopolysaccharides
(depending on the phage family examined), suggesting strong
and context-dependent selection on a trait that is also known
to play a key role in virulence on the plant host (Roach et al.,
2013). Furthermore, Hosseinidoust et al. (2013) found that in
tissue culture, phage-resistant variants of Pseudomonas aeruginosa
actually secrete higher levels of virulence factors and caused more
damage to cultured mammalian cells. With no general pattern yet
emerging, phage-mediated attenuation of virulence seems hard to
predict and certainly not guaranteed. It is possible that a bacterial
pathogen could evolve resistance to a phage therapy product and
maintain or even attain high virulence levels. Furthermore, the
role of compensatory mutations to phage resistance is unknown;
in the case of antibiotics suchmutations can rapidly ameliorate the
costs paid for resistance (Levin et al., 2000; Brandis and Hughes,
2013) and the same may be true of resistance to phages. If this
turns out to be the case, phage therapy treatments that rely on the
loss of costly resistance (or interactions among costly mutations
to multiple phages) will be at constant risk of bacterial escape.
INCREASING HORIZONTAL GENE FLOW THROUGH PHAGE
APPLICATION
In addition to the direct effects of phage application on the densi-
ties and relative frequencies of bacterial pathogens,wemust also be
aware of the potential dangers of phage-mediated horizontal gene
transfer (HGT) among pathogenic and non-pathogenic bacterial
species. This is particularly relevant as HGT is an important driver
of antibiotic resistance evolution (Courvalin, 1994). Given that
phages facilitate horizontal gene ﬂow through the process of trans-
duction and that beta-lactam resistance genes have been isolated
from environmental phage genomes (Colomer-Lluch et al., 2011),
there is clear need to be cautious in our application of phages in
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the environment. Moreover it has recently been shown that antibi-
otic treatment itself expands the number of genes that confer drug
resistance in phage metagenomes (Modi et al., 2013). Environ-
mental perturbation with antibiotics also expanded the ecological
network of phages, suggesting that drug treatment selects for
greater phage-mediated transfer of resistance genes (Modi et al.,
2013). Finally, antibiotic treatment of swine increased the induc-
tion of prophage – another key mechanism of HGT (Allen et al.,
2011).
Phage-mediated transfer of virulence factors is also a key con-
cern, and has been well characterized in the Vibrio cholerae system
whereby CTX  phage (among others) shapes the severity of
cholera pandemics through the transfer of toxin producing vir-
ulence factors and environmental ﬁtness beneﬁts (Faruque and
Mekalanos, 2012). Additionally, V. cholerae has been shown to
becomenaturally competent on a chitin surface (similar to its envi-
ronmental niche on crustacean exoskeletons), facilitating uptake
of exogenous DNA from an array of sources (Meibom et al., 2005),
which could be important if phages are lysing nearby pathogenic
bacterial strains. Environmental perturbation through unnatu-
rally high titers of phages could lead to high levels of transduction
and horizontal gene ﬂow with unintended outcomes, exacerbat-
ing antibiotic resistance and moving virulence factors and toxins
among genomes. However, a better understanding of phage host
range and host range expansion could help mitigate the spread of
genes among bacterial hosts.
IMPACT OF PHAGE APPLICATION ON NATURAL MICROBIAL
COMMUNITIES
The importance of the microbial ﬂora to the ﬁtness of human
hosts has become clear in recent years, with microbes playing
a proposed role in obesity (Greenblum et al., 2012), oral health
(Belda-Ferre et al., 2012), Crohn’s disease (Manichanh et al., 2006),
AIDS (Saxena et al., 2012), and even mental health (Foster and
McVey Neufeld, 2013). Although less well studied, a similar role
of microbiota in shaping ﬁtness is likely to be true for agricultural
plants (Peiffer and Ley, 2013) and livestock (McFall-Ngai et al.,
2013). Whilst antibiotics can disrupt a large proportion of the
microbial community (Dethlefsen and Relman, 2011), phage ther-
apy may facilitate the targeted elimination of a pathogenic strain
without disruption of the normal microbiota of a patient (Carl-
ton, 1999) or a crop plant. Indeed, this argument has been a focal
one to support phage therapy over antibiotic use (Loc-Carrillo
and Abedon, 2011). The term “dysbiosis” has been introduced to
describe a microbial ﬂora that has become“unhealthy,” typically in
human disease (Tamboli, 2004). The same phenomenon is likely
to hold true for natural microbial communities both within and
outside of the host environments, and thus the addition of foreign
phages in the form of a biopesticide could destabilize such com-
munities, causing “dysbiosis” and potentially having subsequent
effects on disease and nutrient cycling. For example, in soil where
ratios of phages to bacteria are expected to be near 1:1 (Reyes et al.,
2010) an inﬂux of applied phages could well disrupt stable ecolog-
ical communities important in nutrient cycling. Conversely, in the
marine environment,where this ratio is closer to 1:100 (Reyes et al.,
2010), an inﬂux of applied phages is unlikely to adversely disrupt
a normal microbial community. Unfortunately, by the same logic,
aquaculture may suffer from lower chances of success from phage
biocontrol, as the concentrations of phages needed to inﬂuence
bacterial density is likely to be a limiting factor.
UNPREDICTABILITY OF INFECTION KINETICS
Unlike antibiotic usage, where an effective dosage can be deter-
mined for different species and corresponding quantities used,
the infection kinetics of phage therapy are less predictable (Payne
and Jansen, 2003). This knowledge gap presents a challenge for
effective use balanced with environmental safety, as an individual
phage persists in the environment for relatively short timescales,
but a lineage can reproduce indeﬁnitely when hosts are plentiful.
This continued replication makes calculations of dosage difﬁcult.
In antibiotic treatment the minimum inhibitory concentration
(MIC) is crucial to informing proper antibiotic dosages; how-
ever, ﬁnding the right balance between a high enough titer of
phages to be effective and not introducing excessive levels into
the environment is difﬁcult. Potentially the application of a sin-
gle phage could lead to the continued replication of an infective
phage, thus perpetuating not only treatment but also persistence
in the environment. If there are unwanted effects of phage biopes-
ticide there are no tools currently available to selectively remove
such viruses from the environment. Also, the timing of treatment
as a function of bacterial density can be crucial for a successful
outcome (Payne and Jansen, 2003). Indeed, in a trial controllingV.
parahaemolyticus infections in shrimp timing was crucial whereas
changes in dosage hadno effect. Reducing themultiplicity of infec-
tion made no difference whereas when treatment was delayed
it was ineffective in controlling mortality (Martínez-Díaz and
Hipólito-Morales, 2013), possibly as a result of non-linear infec-
tion kinetics. Such infection kinetics of phage therapy were tested
in vitro with Campylobacter jejuni, a common poultry pathogen,
and found to ﬁt a non-linear model with a density-dependent pro-
liferation threshold (Cairns et al., 2009). These studies highlight
the nuances involved in effective phage therapy use and as such
the use of phages cannot be analogous to that of antibiotics. Pro-
vided policy makers accept this and approach the ﬁeld balancing
the risks of widespread environmental use with the pressing need
for a clinical alternative to antibiotics, phage biocontrol could be
an integral tool in controlling bacterial diseases.
FUTURE OUTLOOK
Our understanding of the biology, ecology, and evolution of
microbial pathogens has improved immeasurably since the advent
of widespread antibiotic use. If we can learn the lessons from our
mistakes with antibiotic use, phage therapy and biocontrol could
form an integral tool in the ﬁght against bacterial infections that
threaten human health and food production (Pirnay et al., 2012;
Allen et al., 2013). For example, the falling costs of whole genome
sequencing (Kisand and Lettieri, 2013) should make tracking the
evolution and spread of resistance genes in a clinical setting easier
andmore accurate (Didelot et al., 2012). Furthermore, advances in
metagenomics may make monitoring the effects of environmen-
tal perturbations on microbial communities feasible and allow
researchers to track changes over long-time periods. An attractive
avenue of research for pharmaceutical companies may be the use
of phage lysins – enzymes that are capable of bursting bacterial
www.frontiersin.org November 2013 | Volume 4 | Article 358 | 5
“fmicb-04-00358” — 2013/11/28 — 20:30 — page 6 — #6
Meaden and Koskella Exploring the risks of phage application in the environment
cells open “from without.” Such an approach avoids the prob-
lems of infection kinetics mentioned previously and can have
a broad-spectrum encompassing multiple strains of antibiotic
resistant pathogens, such as MRSA and vancomycin intermedi-
ate Staphylococcus aureus (Gilmer et al., 2013). The downside is
that lysins, unlike phages, lack the ability to counter evolve to
pathogens.
Microbial bioﬁlms present a continued risk to healthcare as
they may harbor bacteria in a less metabolically active state
that survive antibiotic treatment (Oliver, 2010). Phages targeting
bioﬁlms in synchrony with antibiotics may form a novel strat-
egy, although the inherent risks of HGT still remain. It may also
be possible to circumvent this cycle of treatment, selection for
resistance and re-infection through the use of “social disruption”
treatments that reduce bacterial virulence without selecting for
resistance (Boyle et al., 2013). Phages could play a role in the
reduction of bioﬁlm and public good production – one exam-
ple is an engineered phage that expresses a bioﬁlm-degrading
enzyme (Lu and Collins, 2007). Whilst this is likely to reduce
the ﬁtness of bacterial populations, selection should be weaker
than that of an antibiotic. Given the difﬁculties faced by clini-
cians in treating antibiotic-resistant infections and the urgency of
ﬁnding alternative therapies, the prudent use of phages should
be a priority. Nevertheless we have the tools to track resistance
and simple measures such as providing a diverse set of phages
for treatment could help. A seasonal-vaccine-like scheme could
create a treatment program that is responsive to the evolution of
resistance. In short, a very different model to that of our use of
antibiotics.
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